Cargando…
Publisher Correction: Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19
Autores principales: | Redhead, Martin A., Owen, C. David, Brewitz, Lennart, Collette, Amelia H., Lukacik, Petra, Strain-Damerell, Claire, Robinson, Sean W., Collins, Patrick M., Schäfer, Philipp, Swindells, Mark, Radoux, Chris J., Hopkins, Iva Navratilova, Fearon, Daren, Douangamath, Alice, von Delft, Frank, Malla, Tika R., Vangeel, Laura, Vercruysse, Thomas, Thibaut, Jan, Leyssen, Pieter, Nguyen, Tu-Trinh, Hull, Mitchell, Tumber, Anthony, Hallett, David J., Schofield, Christopher J., Stuart, David I., Hopkins, Andrew L., Walsh, Martin A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477973/ https://www.ncbi.nlm.nih.gov/pubmed/34584208 http://dx.doi.org/10.1038/s41598-021-99041-1 |
Ejemplares similares
-
Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19
por: Redhead, Martin A., et al.
Publicado: (2021) -
Penicillin Derivatives
Inhibit the SARS-CoV-2
Main Protease by Reaction with Its Nucleophilic Cysteine
por: Malla, Tika R., et al.
Publicado: (2022) -
Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS‐CoV‐2 Papain‐Like Protease
por: Brewitz, Lennart, et al.
Publicado: (2022) -
Mass spectrometry reveals potential of β-lactams as SARS-CoV-2 M(pro) inhibitors
por: Malla, Tika R., et al.
Publicado: (2021) -
In vitro selection of macrocyclic peptide inhibitors containing cyclic γ(2,4)-amino acids targeting the SARS-CoV-2 main protease
por: Miura, Takashi, et al.
Publicado: (2023)